288 related articles for article (PubMed ID: 22383993)
1. A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
Sampson JH; Schmittling RJ; Archer GE; Congdon KL; Nair SK; Reap EA; Desjardins A; Friedman AH; Friedman HS; Herndon JE; Coan A; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Mitchell DA
PLoS One; 2012; 7(2):e31046. PubMed ID: 22383993
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Mitchell DA; Cui X; Schmittling RJ; Sanchez-Perez L; Snyder DJ; Congdon KL; Archer GE; Desjardins A; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Sampson JH
Blood; 2011 Sep; 118(11):3003-12. PubMed ID: 21768296
[TBL] [Abstract][Full Text] [Related]
3. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.
Rech AJ; Mick R; Martin S; Recio A; Aqui NA; Powell DJ; Colligon TA; Trosko JA; Leinbach LI; Pletcher CH; Tweed CK; DeMichele A; Fox KR; Domchek SM; Riley JL; Vonderheide RH
Sci Transl Med; 2012 May; 4(134):134ra62. PubMed ID: 22593175
[TBL] [Abstract][Full Text] [Related]
4. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.
Locke FL; Pidala J; Storer B; Martin PJ; Pulsipher MA; Chauncey TR; Jacobsen N; Kröger N; Walker I; Light S; Shaw BE; Beato F; Laport GG; Nademanee A; Keating A; Socie G; Anasetti C
Biol Blood Marrow Transplant; 2017 Mar; 23(3):405-411. PubMed ID: 28007665
[TBL] [Abstract][Full Text] [Related]
5. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
[TBL] [Abstract][Full Text] [Related]
6. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.
Rech AJ; Vonderheide RH
Ann N Y Acad Sci; 2009 Sep; 1174():99-106. PubMed ID: 19769742
[TBL] [Abstract][Full Text] [Related]
8. In vivo maintenance of human regulatory T cells during CD25 blockade.
Huss DJ; Mehta DS; Sharma A; You X; Riester KA; Sheridan JP; Amaravadi LS; Elkins JS; Fontenot JD
J Immunol; 2015 Jan; 194(1):84-92. PubMed ID: 25416807
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
[TBL] [Abstract][Full Text] [Related]
10. Disengaging the IL-2 receptor with daclizumab enhances IL-7-mediated proliferation of CD4(+) and CD8(+) T cells.
Monti P; Brigatti C; Heninger AK; Scirpoli M; Bonifacio E
Am J Transplant; 2009 Dec; 9(12):2727-35. PubMed ID: 19788505
[TBL] [Abstract][Full Text] [Related]
11. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy.
Kühnöl C; Herbarth M; Föll J; Staege MS; Kramm C
Cancer Immunol Immunother; 2013 Dec; 62(12):1797-809. PubMed ID: 24129764
[TBL] [Abstract][Full Text] [Related]
12. Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling.
Tkaczuk J; Yu CL; Baksh S; Milford EL; Carpenter CB; Burakoff SJ; McKay DB
Am J Transplant; 2002 Jan; 2(1):31-40. PubMed ID: 12095053
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of immunosuppression by the therapeutic antibody daclizumab.
Yang H; Wang J; Du J; Zhong C; Zhang D; Guo H; Guo Y; Ding J
Cell Res; 2010 Dec; 20(12):1361-71. PubMed ID: 20820193
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.
Koch M; Niemeyer G; Patel I; Light S; Nashan B
Transplantation; 2002 May; 73(10):1640-6. PubMed ID: 12042653
[TBL] [Abstract][Full Text] [Related]
15. Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus.
Sivanandham R; Kleinman AJ; Sette P; Brocca-Cofano E; Kilapandal Venkatraman SM; Policicchio BB; He T; Xu C; Swarthout J; Wang Z; Pandrea I; Apetrei C
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669326
[TBL] [Abstract][Full Text] [Related]
16. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
[TBL] [Abstract][Full Text] [Related]
17. Non-IL-2-blocking anti-CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti-CTLA-4 therapy.
Peng Y; Fu Y; Liu H; Zhao S; Deng H; Jiang X; Lai Q; Lu Y; Guo C; Zhang G; Luo Y; Wang Y; Gou L; Yang J
Int J Cancer; 2024 Apr; 154(7):1285-1297. PubMed ID: 38180065
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
Perry JS; Han S; Xu Q; Herman ML; Kennedy LB; Csako G; Bielekova B
Sci Transl Med; 2012 Aug; 4(145):145ra106. PubMed ID: 22855463
[TBL] [Abstract][Full Text] [Related]
19. Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab.
Tkaczuk J; Milford E; Yu C; Baksh S; Carpenter C; Burakoff S; McKay D
Transplant Proc; 2001; 33(1-2):212-3. PubMed ID: 11266783
[No Abstract] [Full Text] [Related]
20. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
Berkowitz JL; Janik JE; Stewart DM; Jaffe ES; Stetler-Stevenson M; Shih JH; Fleisher TA; Turner M; Urquhart NE; Wharfe GH; Figg WD; Peer CJ; Goldman CK; Waldmann TA; Morris JC
Clin Immunol; 2014 Dec; 155(2):176-87. PubMed ID: 25267440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
